04.24.07
Indication: Climacteric symptoms (postmenopausal women)
Source: Menopause, Jan-Feb 2007;14(1):89-96.
Research: Seventy-four postmenopausal women with climacteric symptoms were treated with Remifemin (5 mg dry extract per day, corresponding to 40 mg herbal substance)-65 women actually completed the study. Mammograms were performed and breast cells were collected by fine needle aspiration biopsies at baseline and after six months. Mammographic density was quantified according to Wolfe classification or a percentage scale. Breast cell proliferation was assessed using the ki-67/MIB-1 monoclonal antibody. Safety was monitored by adverse event reporting, laboratory assessments and measurements of the endometrium by vaginal ultrasound.
Results: According to researchers, none of the women studied show any increase in mammographic breast density. Further, there was no increase in breast cell proliferation. Therefore, the findings suggest that Remifemin black cohosh does not cause adverse effects on breast tissue. And, the data do not indicate any endometrial or general safety concerns during six month of treatment.